Sign in
Taking people in United StatesNo phase

How Clonal Hematopoiesis Affects People Treated With Chemotherapy and Radiation for Solid Cancers

Studies how clonal hematopoiesis relates to outcomes in adults treated for solid cancers.

Key facts

Who runs it
Dana-Farber Cancer Institute
Where
Boston, United StatesSee the site
Trial code
Registry title
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Status
Recruiting
People taking part
5,000 people, planned
Started
4 Apr 2025
Expected to end
31 Mar 2035
Type of study
Observational, 3 groups
Treatments tested
  • Samples
Record updated
30 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid cancer who are about to start chemotherapy or radiation for the first time. It studies blood changes called clonal hematopoiesis.

Age
Adults over 18 years
Sex
All sexes
Disease stage
Solid cancer: breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma.
Earlier treatment
Must not have had chemotherapy or radiation before for this solid cancer. Must have a plan to receive chemotherapy or radiation.

Main reasons for not taking part

  • No plan for chemotherapy, radiation or PARP inhibitor treatment
  • Chemotherapy or radiation already received for the current solid cancer
  • Any past blood cancer, such as leukemia, myelodysplastic syndrome, lymphoma or multiple myeloma

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants to be included in this study include the following:
  • Adults age >18 years
  • Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)
  • Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer)
  • Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past

Who cannot take part

  • Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure
  • Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)
  • Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation

Where in United States

  • Dana-Farber Cancer InstituteBoston, United StatesContact: Cindy Amaya Lopez, BATaking people

About the trial

What the trial wants to find out

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.

Read full original descriptionShow less

The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).

Ultimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.

The 3 groups in the trial

  • HEREDITARY RISK

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.

    Treatment: Samples

  • EXPOSED HIGH RISK

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.

    Treatment: Samples

  • PRECURSOR LESIONS

    Participants will also be asked to complete an intake survey that will include questions about demographics, medical history and family history data. Tissue samples will be collected during a routine visit or at patient's home via remote collection. Participants will be asked to donate any the following tissue types: - Blood - Buccal swab (saliva) or mouthwash.

    Treatment: Samples

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Plain-language title
How Clonal Hematopoiesis Affects People Treated With Chemotherapy and Radiation for Solid CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
30 June 2026